OncoMatch/Clinical Trials/NCT06828991
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
Is NCT06828991 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Mosunetuzumab and ClonoSEQ for diffuse large b-cell lymphoma (dlbcl).
Treatment: Mosunetuzumab · ClonoSEQ — Older patients with diffuse large B- cell lymphoma (DLBCL) do not have the same rates of disease control as younger patients and are at risk for toxicity. Identifying which patients might benefit from more therapy at the end of first-line treatment is important. The ability to measure small amounts of persistent lymphoma (circulating tumor DNA or ctDNA) might allow the investigators to risk stratify patients. If older patients have detectable ctDNA in the blood at the end of six cycles of polatuzumab vedotin, rituximab and dose-attentuated CHP chemotherapy, patients will receive a bispecific antibody called mosunetuzumab. The investigators hypothesize this will result in "clearing" the ctDNA from the blood and result in better disease control and outcomes for patients. The study will also measure the safety of this regimen and the impact on the function of these older patients utilizing a tool called the geriatric assessment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Allowed: BCL2 rearrangement
Allowed: MYC rearrangement
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anthracycline
Exception: one cycle of anthracycline containing chemotherapy prior to enrollment is allowed
must not have received an anthracycline-containing regimen in the past
Cannot have received: investigational drug
Patient has received other investigational drugs within 28 days before enrollment
Lab requirements
Blood counts
platelet count ≥75,000/µL (or ≥30,000/µL if due to marrow infiltration); ANC ≥1,500/µL (or ≥500/µL if due to marrow infiltration)
Kidney function
creatinine clearance >40 mL/minute
Liver function
Total bilirubin <1.5x ULN unless due to Gilbert syndrome or hepatic involvement (≤3.0x ULN); ALT or AST ≤2.5x ULN
Cardiac function
ejection fraction ≥45% on echocardiogram or MUGA
Ejection fraction of ≥ 45% on echocardiogram or MUGA; platelet count of ≥75,000/µL unless due to marrow infiltration (≥30,000/µL); ANC ≥1,500/µL unless due to marrow infiltration (≥500/µL); creatinine clearance >40 mL/minute; Total bilirubin <1.5x ULN unless due to Gilbert syndrome or hepatic involvement (≤3.0x ULN); ALT or AST ≤2.5x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Wilmot Cancer Institute · Rochester, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify